Adrenomedullin and tumour angiogenesis: Minireview
The angiogenic activity of peptide adrenomedullin (AM) was first shown in 1998 . Since then, a number of reports have confirmed the ability of AM to induce the growth and migration of isolated vascular endothelial and smooth muscle cells in vitro and to promote angiogenesis in xenografted tumours in...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2006-01, Vol.94 (1), p.1-7 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | British journal of cancer |
| container_volume | 94 |
| creator | Nikitenko, L L Fox, S B Kehoe, S Rees, M C P Bicknell, R |
| description | The angiogenic activity of peptide adrenomedullin (AM) was first shown in 1998 . Since then, a number of reports have confirmed the ability of AM to induce the growth and migration of isolated vascular endothelial and smooth muscle cells
in vitro
and to promote angiogenesis in xenografted tumours
in vivo.
In addition, knockout murine models point to an essential role for AM in embryonic vasculogenesis and ischaemic revascularisation. AM expression is upregulated by hypoxia (a typical feature of solid tumours) and a potential role as a regulator of carcinogenesis and tumour progression has been proposed based on studies
in vitro
and in animal models. Nevertheless, translational research on AM, and in particular, confirmation of its importance in the vascularisation of human tumours has lagged behind. In this commentary, we review current progress and potential directions for future research into the role of AM in tumour angiogenesis. |
| doi_str_mv | 10.1038/sj.bjc.6602832 |
| format | Article |
| fullrecord | <record><control><sourceid>springer</sourceid><recordid>TN_cdi_springer_journals_10_1038_sj_bjc_6602832</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1038_sj_bjc_6602832</sourcerecordid><originalsourceid>FETCH-springer_journals_10_1038_sj_bjc_66028323</originalsourceid><addsrcrecordid>eNqVjssKwjAURC-iYH1sXXflru1Ngm26FFH8APehNbEktKnk2v83Qn_A1cwwHDgAB4Y5QyELcnnrnnlZIpeCLyBhJ8EzJnm1hAQRqwxrjmvYELk4a5RVAsezDsaPg9FT31ufNl6nn2kYpxBrZ8fOeEOWdrB6NT2Z_ZxbKG7Xx-We0TtY35mgXER8vBRD9dNR5FTUUbOO-J_4AsEZPqk</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adrenomedullin and tumour angiogenesis: Minireview</title><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nikitenko, L L ; Fox, S B ; Kehoe, S ; Rees, M C P ; Bicknell, R</creator><creatorcontrib>Nikitenko, L L ; Fox, S B ; Kehoe, S ; Rees, M C P ; Bicknell, R</creatorcontrib><description>The angiogenic activity of peptide adrenomedullin (AM) was first shown in 1998 . Since then, a number of reports have confirmed the ability of AM to induce the growth and migration of isolated vascular endothelial and smooth muscle cells
in vitro
and to promote angiogenesis in xenografted tumours
in vivo.
In addition, knockout murine models point to an essential role for AM in embryonic vasculogenesis and ischaemic revascularisation. AM expression is upregulated by hypoxia (a typical feature of solid tumours) and a potential role as a regulator of carcinogenesis and tumour progression has been proposed based on studies
in vitro
and in animal models. Nevertheless, translational research on AM, and in particular, confirmation of its importance in the vascularisation of human tumours has lagged behind. In this commentary, we review current progress and potential directions for future research into the role of AM in tumour angiogenesis.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6602832</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Drug Resistance ; Epidemiology ; mini-review ; Molecular Medicine ; Oncology</subject><ispartof>British journal of cancer, 2006-01, Vol.94 (1), p.1-7</ispartof><rights>The Author(s) 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Nikitenko, L L</creatorcontrib><creatorcontrib>Fox, S B</creatorcontrib><creatorcontrib>Kehoe, S</creatorcontrib><creatorcontrib>Rees, M C P</creatorcontrib><creatorcontrib>Bicknell, R</creatorcontrib><title>Adrenomedullin and tumour angiogenesis: Minireview</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>The angiogenic activity of peptide adrenomedullin (AM) was first shown in 1998 . Since then, a number of reports have confirmed the ability of AM to induce the growth and migration of isolated vascular endothelial and smooth muscle cells
in vitro
and to promote angiogenesis in xenografted tumours
in vivo.
In addition, knockout murine models point to an essential role for AM in embryonic vasculogenesis and ischaemic revascularisation. AM expression is upregulated by hypoxia (a typical feature of solid tumours) and a potential role as a regulator of carcinogenesis and tumour progression has been proposed based on studies
in vitro
and in animal models. Nevertheless, translational research on AM, and in particular, confirmation of its importance in the vascularisation of human tumours has lagged behind. In this commentary, we review current progress and potential directions for future research into the role of AM in tumour angiogenesis.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>mini-review</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNqVjssKwjAURC-iYH1sXXflru1Ngm26FFH8APehNbEktKnk2v83Qn_A1cwwHDgAB4Y5QyELcnnrnnlZIpeCLyBhJ8EzJnm1hAQRqwxrjmvYELk4a5RVAsezDsaPg9FT31ufNl6nn2kYpxBrZ8fOeEOWdrB6NT2Z_ZxbKG7Xx-We0TtY35mgXER8vBRD9dNR5FTUUbOO-J_4AsEZPqk</recordid><startdate>20060116</startdate><enddate>20060116</enddate><creator>Nikitenko, L L</creator><creator>Fox, S B</creator><creator>Kehoe, S</creator><creator>Rees, M C P</creator><creator>Bicknell, R</creator><general>Nature Publishing Group UK</general><scope>C6C</scope></search><sort><creationdate>20060116</creationdate><title>Adrenomedullin and tumour angiogenesis</title><author>Nikitenko, L L ; Fox, S B ; Kehoe, S ; Rees, M C P ; Bicknell, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-springer_journals_10_1038_sj_bjc_66028323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>mini-review</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nikitenko, L L</creatorcontrib><creatorcontrib>Fox, S B</creatorcontrib><creatorcontrib>Kehoe, S</creatorcontrib><creatorcontrib>Rees, M C P</creatorcontrib><creatorcontrib>Bicknell, R</creatorcontrib><collection>Springer Nature OA Free Journals</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nikitenko, L L</au><au>Fox, S B</au><au>Kehoe, S</au><au>Rees, M C P</au><au>Bicknell, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adrenomedullin and tumour angiogenesis: Minireview</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><date>2006-01-16</date><risdate>2006</risdate><volume>94</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>The angiogenic activity of peptide adrenomedullin (AM) was first shown in 1998 . Since then, a number of reports have confirmed the ability of AM to induce the growth and migration of isolated vascular endothelial and smooth muscle cells
in vitro
and to promote angiogenesis in xenografted tumours
in vivo.
In addition, knockout murine models point to an essential role for AM in embryonic vasculogenesis and ischaemic revascularisation. AM expression is upregulated by hypoxia (a typical feature of solid tumours) and a potential role as a regulator of carcinogenesis and tumour progression has been proposed based on studies
in vitro
and in animal models. Nevertheless, translational research on AM, and in particular, confirmation of its importance in the vascularisation of human tumours has lagged behind. In this commentary, we review current progress and potential directions for future research into the role of AM in tumour angiogenesis.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/sj.bjc.6602832</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2006-01, Vol.94 (1), p.1-7 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_springer_journals_10_1038_sj_bjc_6602832 |
| source | Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biomedical and Life Sciences Biomedicine Cancer Research Drug Resistance Epidemiology mini-review Molecular Medicine Oncology |
| title | Adrenomedullin and tumour angiogenesis: Minireview |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A18%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-springer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adrenomedullin%20and%20tumour%20angiogenesis:%20Minireview&rft.jtitle=British%20journal%20of%20cancer&rft.au=Nikitenko,%20L%20L&rft.date=2006-01-16&rft.volume=94&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/sj.bjc.6602832&rft_dat=%3Cspringer%3E10_1038_sj_bjc_6602832%3C/springer%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |